Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report

Immunotherapy has been proved to be a promising candidate for advanced non-small cell lung cancer (NSCLC). Despite MET mutations are regarded as an independent factor of programmed death ligand 1 (PD-L1) high expression, the efficacy of immune checkpoint inhibitors (ICIs) across NSCLC harboring Mese...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhuxing, Zhu, Feng, Li, Caichen, Li, Jianfu, Cheng, Bo, Xiong, Shan, Zhong, Ran, Liang, Wenhua, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033371/
https://www.ncbi.nlm.nih.gov/pubmed/33842645
http://dx.doi.org/10.21037/atm-20-6829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033371/
https://www.ncbi.nlm.nih.gov/pubmed/33842645
http://dx.doi.org/10.21037/atm-20-6829

Ejemplares similares